Utilizing signature-score to identify oncogenic pathways of cholangiocarcinoma.
暂无分享,去创建一个
Charles Keller | Tzu-Hung Hsiao | Jo-Yang Lu | Yidong Chen | C. Keller | Yidong Chen | T. Hsiao | G. Tomlinson | Hung-I Harry Chen | Pei Lin | Gail E Tomlinson | H. Chen | S. Comerford | Pei-Ying Lin | Sarah Comerford | Jo-Yang Lu
[1] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[2] F. Eckel,et al. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials , 2007, British Journal of Cancer.
[3] Benjamin R Arenkiel,et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. , 2011, Cancer cell.
[4] S. Thorgeirsson,et al. Progenitor‐derived hepatocellular carcinoma model in the rat , 2010, Hepatology.
[5] S. Thorgeirsson,et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.
[6] Justin Guinney,et al. Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting , 2011, PloS one.
[7] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[8] B. Yoong,et al. Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. , 2012, World journal of gastroenterology.
[9] A. Olshen,et al. Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas , 2007, The Journal of pathology.
[10] P. Callard,et al. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections , 1988, The Journal of pathology.
[11] Michael L. Gatza,et al. A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.
[12] S. Serra,et al. The Use of Cytokeratin 19 (CK19) Immunohistochemistry in Lesions of the Pancreas, Gastrointestinal Tract, and Liver , 2010, Applied immunohistochemistry & molecular morphology : AIMM.
[13] G. Fava. Molecular mechanisms of cholangiocarcinoma. , 2010, World journal of gastrointestinal pathophysiology.
[14] Seiichi Mori,et al. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. , 2008, Cancer cell.
[15] H. El‐Serag,et al. The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.
[16] A. Chinnaiyan,et al. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.
[17] Y. Konishi,et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. , 1995, Gastroenterology.
[18] Ash A. Alizadeh,et al. Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.
[19] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[20] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[21] S. Thorgeirsson,et al. Transforming growth factor‐β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer , 2008, Hepatology.
[22] R. Young,et al. A common set of gene regulatory networks links metabolism and growth inhibition. , 2004, Molecular cell.
[23] K. Arihiro,et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. , 2005, International journal of oncology.
[24] W. Palmer,et al. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.
[25] Jin Woo Kim,et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.
[26] Dror Berel,et al. Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma , 2009, PloS one.
[27] A. Chinnaiyan,et al. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.
[28] P. Bosma,et al. Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma. , 2006, Journal of hepatology.
[29] Itzhak Avital,et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.
[30] Shuta Tomida,et al. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. , 2009, Cancer research.
[31] Harada,et al. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma , 1999, Histopathology.
[32] Hideaki Mizuno,et al. A signature-based method for indexing cell cycle phase distribution from microarray profiles , 2009, BMC Genomics.
[33] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[34] R. Hruban,et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts , 2001, Cancer.
[35] M. Grever,et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] Jung-Hwan Yoon,et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.